Corbus Pharmaceuticals (CRBP) PT Raised to $57 at Oppenheimer

March 10, 2026 8:12 AM

Oppenheimer analyst Jeff Jones raised the price target on Corbus Pharmaceuticals (NASDAQ: CRBP) to $57.00 (from $53.00) while maintaining a Outperform rating.

No results found